Last reviewed · How we verify
Metronidazole 250 (14 days)
Metronidazole disrupts bacterial and parasitic DNA by generating reactive oxygen species and damaging their genetic material.
Metronidazole disrupts bacterial and parasitic DNA by generating reactive oxygen species and damaging their genetic material. Used for Anaerobic bacterial infections, Trichomoniasis, Amebiasis.
At a glance
| Generic name | Metronidazole 250 (14 days) |
|---|---|
| Sponsor | University of Guarulhos |
| Drug class | Nitroimidazole antimicrobial |
| Target | Bacterial/parasitic DNA |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
Metronidazole is a prodrug that is activated by anaerobic organisms and parasites to form reactive intermediates that bind to and cleave DNA, preventing replication and transcription. It is effective against anaerobic bacteria and certain protozoan parasites. The drug is particularly useful in infections where oxygen is limited, as it requires anaerobic conditions for activation.
Approved indications
- Anaerobic bacterial infections
- Trichomoniasis
- Giardiasis
- Amebiasis
- Clostridioides difficile infection
- Bacterial vaginosis
Common side effects
- Metallic taste
- Nausea
- Headache
- Diarrhea
- Peripheral neuropathy
- Disulfiram-like reaction with alcohol
Key clinical trials
- Efficacies of Susceptibility-guided vs Empiric Therapy for Rescue Treatment of Helicobacter Pylori Infection (PHASE4)
- The Use of Low Dose Metronidazole to Decrease Postoperative Pain After Endometriosis Surgery (PHASE4)
- Optimal Duration of Bismuth Quadruple Therapy for Helicobacter Pylori Eradication in Females As Compared with Males (PHASE4)
- The Efficacy of 10-day and 14-day Bismuth-based Quadruple Therapy in First-line H. Pylori Eradication (PHASE4)
- Comparing the Efficacy of Hybrid, High-dose Dual and Bismuth Quadruple Therapies (PHASE3)
- Ceftolozane/Tazobactam (MK-7625A) Plus Metronidazole Versus Meropenem for Participants With Complicated Intra-abdominal Infection (MK-7625A-015) (PHASE3)
- Randomized Trial Comparing Prevena and ActiV.A.C. System to Convetional Care After Bascom's Cleft Lift Surgery (NA)
- Trial of Antimicrobials Versus Placebo in Addition to Fecal Transplant Therapy in Ulcerative Colitis (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Metronidazole 250 (14 days) CI brief — competitive landscape report
- Metronidazole 250 (14 days) updates RSS · CI watch RSS
- University of Guarulhos portfolio CI